WEREWOLF THERAPEUTICS, INC. Accretion Expense
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Accretion Expense of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2023-03-23
- WEREWOLF THERAPEUTICS, INC. accretion expense for the quarter ending 2022-12-31 was $0.00.
- WEREWOLF THERAPEUTICS, INC. accretion expense for the quarter ending 2022-09-30 was $0.00.
- WEREWOLF THERAPEUTICS, INC. accretion expense for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. accretion expense for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. accretion expense for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- WEREWOLF THERAPEUTICS, INC. accretion expense for fiscal 2021 was $151.94M, a 1053.08% increase from fiscal 2020.
- WEREWOLF THERAPEUTICS, INC. accretion expense for fiscal 2020 was $13.18M.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $0.00 derived: sum of 3 quarters · filed 2023-03-23 | $0.00 10-K · filed 2023-03-23 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | $0.00 derived: sum of 4 quarters · filed 2023-03-23 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | $0.00 derived: sum of 3 quarters · filed 2023-03-23 | $0.00 derived: sum of 4 quarters · filed 2023-03-23 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-10 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $0.00 derived: sum of 3 quarters · filed 2023-03-23 | $56.93M derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $56.93M derived: sum of 3 quarters · filed 2023-03-23 | $151.94M 10-K · filed 2023-03-23 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $56.93M derived: sum of 2 quarters · filed 2022-11-10 | $151.94M 10-Q · filed 2022-11-10 | $165.09M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $56.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $151.94M 10-Q · filed 2022-08-11 | $165.09M derived: sum of 3 quarters · filed 2022-08-11 | $165.09M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $95.02M 10-Q · filed 2022-05-10 | $108.16M derived: sum of 2 quarters · filed 2022-05-10 | $108.16M derived: sum of 3 quarters · filed 2022-05-10 | $108.19M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $13.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $13.15M derived: sum of 2 quarters · filed 2022-03-24 | $13.18M derived: sum of 3 quarters · filed 2022-03-24 | $13.18M 10-K · filed 2022-03-24 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $31.00K derived: sum of 2 quarters · filed 2021-11-10 | $31.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $31.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $31.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |